» Articles » PMID: 11569527

Utility of Metabolic Stability Screening: Comparison of in Vitro and in Vivo Clearance

Overview
Journal Xenobiotica
Publisher Informa Healthcare
Specialties Biochemistry
Toxicology
Date 2001 Sep 25
PMID 11569527
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

1. The ability of hepatic microsomal metabolic stability assessments to predict in vivo clearance in rat has been retrospectively evaluated for 1,163 compounds from 48 programmes of chemistry. Using a simple binary classification system, the in vivo clearances of approximately 64% of the compounds were correctly classified. 2. About 24% of compounds were metalbolically stable yet had clearance greater than half of liver blood flow in vivo. This might be expected as microsomes only contain a limited number of fully functioning drug-metabolizing enzymes and cannot be expected to account for extrahepatic or non-metabolic clearance processes. 3. About 13% of compounds had in vivo clearances of less than half liver blood flow despite being classified as metabolically unstable. Despite overcoming metabolic instability, these compounds had other undesirable properties and were generally more highly bound to plasma proteins, had smaller volumes of distribution (and shorter half-lives despite their clearance) and were more inhibitory against the major human cytochrome P450s. 4. Taking plasma protein binding into consideration reduced the proportion of misclassified low-clearance compounds but did not improve the overall success appreciably. Somewhat surprisingly, human microsomes were nearly as effective as rat microsomes at classifying rat in vivo clearance.

Citing Articles

Discovery of RC-752, a Novel Sigma-1 Receptor Antagonist with Antinociceptive Activity: A Promising Tool for Fighting Neuropathic Pain.

Rossino G, Marra A, Listro R, Peviani M, Poggio E, Curti D Pharmaceuticals (Basel). 2023; 16(7).

PMID: 37513874 PMC: 10386076. DOI: 10.3390/ph16070962.


Induction of Ferroptosis in Glioblastoma and Ovarian Cancers by a New Pyrrole Tubulin Assembly Inhibitor.

Puxeddu M, Wu J, Bai R, DAmbrosio M, Nalli M, Coluccia A J Med Chem. 2022; 65(23):15805-15818.

PMID: 36395526 PMC: 9743090. DOI: 10.1021/acs.jmedchem.2c01457.


Assessment of Pharmacokinetics and Metabolism Profiles of SCH 58261 in Rats Using Liquid Chromatography-Mass Spectrometric Method.

Park Y, Park M, Byeon J, Shin S, Lee B, Choi J Molecules. 2020; 25(9).

PMID: 32397307 PMC: 7248953. DOI: 10.3390/molecules25092209.


Pharmacological Comparisons Between Cannabidiol and KLS-13019.

Brenneman D, Petkanas D, Kinney W J Mol Neurosci. 2018; 66(1):121-134.

PMID: 30109468 PMC: 6150782. DOI: 10.1007/s12031-018-1154-7.


Tissue Engineering Approaches in the Design of Healthy and Pathological Tissue Models.

Caddeo S, Boffito M, Sartori S Front Bioeng Biotechnol. 2017; 5:40.

PMID: 28798911 PMC: 5526851. DOI: 10.3389/fbioe.2017.00040.